Neutropenia Treatment Market Expected to Reach $19,303.1 Million by 2027

According to a new report published by Allied Market Research, titled, “Neutropenia Treatment Market by Treatment (Colony-stimulating factors, Antibiotics, Antifungals and Antivirals), by Distribution Channel (Hospital pharmacies, Retail pharmacies and Online pharmacies):  Opportunity Analysis and Industry Forecast, 2019–2027,”the global neutropenia market size is expected to reach $19,303.1 million by 2027, registering a CAGR of 5.4% from 2020 to 2027, in terms of value.

Neutropenia is a disease in which the amount of white blood cells (neutrophils) in the blood supply is decreased, reducing the capacity of the body to combat infections. Neutropenia is defined as an absolute count of neutrophils (ANC) below 1500 per microliter (1500/microL); severe neutropenia is defined as an ANC below 500/microL.

Neutrophils play an important role in immune defenses because they ingest, kill, and digest invading microbes such as fungi and bacteria. Neutropenia is a disease associated with low white blood cell count. These white blood cells are called neutrophils. Further, some of the major causes for neutropenia are cancer chemotherapy, radiation therapy stem cell, or bone marrow transplants. The treatment for neutropenia is dependent on the underlying cause, severity, and associated infections related to overall health of patients. 

The neutropenia market is expected to register a substantial growth in the future, owing to rise in incidences of cancer cases. In addition, increase in R&D efforts by companies to develop novel therapies for treatment of neutropenia is expected to boost the market growth during the forecast period. 

However, high cost of treatment of neutropenia and stringent rules and regulations for product approvals are anticipated to hamper the neutropenia treatment market growth during the forecast period. On the contrary, fundamental shift from branded drugs to low cost biosimilars is expected to provide remunerative opportunities for the market players.

The neutropenia cancer market is segmented on the basis of treatment and distribution channel. By treatment, it is categorized into colony-stimulating factor, antibiotics, and antifungals. Colony-stimulating factors are secreted glycoproteins. These bind to receptor proteins on the surface of hematopoietic stem cells. The colony-stimulating factors are of two types, namely, granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF). 

On the basis of distribution channel, it is divided into hospitals pharmacies, retail pharmacies, and online pharmacies. Neutropenia treatment drugs are marketed by various sales channel such as pharmacies, within the hospitals. These medications are also offered by online providers through registered websites, which offer the ease of ordering medicines over the internet. The retail pharmacies segment is expected to dominate the global neutropenia market, owing to adequate supply of products and easy availability and accessibility of retail pharmacies. Online pharmacies are projected to generate significant revenue in the global neutropenia treatment market during the forecast period.

The global neutropenia treatment market is segmented on the basis of region into North America (the U.S., Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, and rest of Asia-Pacific), LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA). 

North America accounted for the largest the global neutropenia treatment market share. The neutropenia treatment market witnessed a vast growth in North America and is expected to dominate the market in the coming years. This is attributed to the increase in incidences of leukemia in the region. According to the International Agency for Research on Cancer, in 2018, 169,270 people are living with leukemia for five years and 58,876 new leukemia cases were diagnosed in North America. In addition, major key players of the market operate in North America. Further, the demand for neutropenia treatment in North America is dominated by the US. The dominance of the region is due to a rise in demand for medicinal needs for febrile neutropenia and introduction of new legislation for promotion and production of biosimilars. 

Asia-Pacific is expected to witness highest growth rate in the market throughout the forecast period. Asia possesses high potential for the growth of neutropenia treatment market, owing to leukemia cases and number of patients undergoing first-line chemotherapy treatment. 

The key players operating in the neutropenia market include Amgen, BeyondSpring, Kyowa Kirin, Cellerant Therapeutics, Mylan N.V., Novartis AG, Partner Therapeutics, Pfizer, Spectrum Pharmaceuticals and Teva Pharmaceutical Industries Ltd. Other players neutropenia market (not profiled in the report) include Myelo Therapeutics, Enzychem Lifesciences Corporation Samsung Medical Center and among others. 

Key Findings Of The Study

• Based on treatment, the colony-stimulating factors segment accounted for a $10, 211.5 in the global neutropenia market in 2019.

• Based on distribution channel, the hospital pharmacies segment account for the largest share and the online pharmacies segment is anticipated to grow with the highest CAGR of 6.0% throughout the forecast period.